Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019 (COVID-19)
illness were available within a year of the pandemic being declared but there …
illness were available within a year of the pandemic being declared but there …
Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID‐19 trial of nirmatrelvir
RSP Singh, SS Toussi, F Hackman… - Clinical …, 2022 - Wiley Online Library
Coronavirus disease 2019 (COVID‐19) is a continued leading cause of hospitalization and
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF‐07321332…
death. Safe, efficacious COVID‐19 antivirals are needed urgently. Nirmatrelvir (PF‐07321332…
Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID‐19, in subjects with renal impairment
SS Toussi, JM Neutel, J Navarro… - Clinical …, 2022 - Wiley Online Library
Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of
coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk of …
coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk of …
Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor–α inhibitors: systematic …
SS Toussi, N Pan, HM Walters… - Clinical infectious …, 2013 - academic.oup.com
Tumor necrosis factor alpha (TNF-α) inhibitors are increasingly administered to children and
adolescents with juvenile idiopathic arthritis (JIA) and pediatric inflammatory bowel disease (…
adolescents with juvenile idiopathic arthritis (JIA) and pediatric inflammatory bowel disease (…
(1→3)-β- d -Glucan in Cerebrospinal Fluid as a Biomarker for Candida and Aspergillus Infections of the Central Nervous …
CM Salvatore, TK Chen, SS Toussi… - Journal of the …, 2016 - academic.oup.com
Background Fungal infections of the central nervous system (FICNS) are important causes
of morbidity and mortality among immunocompromised pediatric patients. Standard …
of morbidity and mortality among immunocompromised pediatric patients. Standard …
Metabolism and excretion of nirmatrelvir in humans using quantitative fluorine nuclear magnetic resonance spectroscopy: a novel approach for accelerating drug …
…, L Van Eyck, F Hackman, SS Toussi… - Clinical …, 2022 - Wiley Online Library
Typically human absorption, distribution, metabolism, and excretion (ADME) studies are
executed using radiolabeled (eg, carbon‐14) material, the synthesis of which is a time‐…
executed using radiolabeled (eg, carbon‐14) material, the synthesis of which is a time‐…
NASPGHAN clinical report: surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor …
MI Ardura, SS Toussi, JD Siegel, Y Lu… - Journal of pediatric …, 2016 - journals.lww.com
Children and adolescents with inflammatory bowel disease (IBD) receiving therapy with tumor
necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care providers …
necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care providers …
A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha …
…, S Cunningham-Rundles, TJ Walsh, SS Toussi - Clinical …, 2015 - Springer
Tumor necrosis factor-alpha (TNF-α) inhibitors are effective treatment for juvenile idiopathic
arthritis (JIA) but may increase infection rates. However, active JIA may also render patients …
arthritis (JIA) but may increase infection rates. However, active JIA may also render patients …
Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF‐07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS‐CoV‐2, in …
T Zhu, S Pawlak, SS Toussi, F Hackman… - Clinical …, 2022 - Wiley Online Library
Studies on targeted antivirals for treatment of severe acute respiratory syndrome coronavirus
2 (SARS‐CoV‐2), the cause of the ongoing pandemic, are limited. PF‐07304814 (lufotrelvir…
2 (SARS‐CoV‐2), the cause of the ongoing pandemic, are limited. PF‐07304814 (lufotrelvir…
The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration
…, E van Duijn, PA Spigt, IM Barbu, SS Toussi… - Drug Metabolism and …, 2023 - ASPET
The metabolism of lufotrelvir, a novel phosphate prodrug of PF-00835231 for the treatment
of COVID-19, was evaluated in healthy human volunteers and clinical trial participants with …
of COVID-19, was evaluated in healthy human volunteers and clinical trial participants with …
